Imagine a world where your local pharmacy, a trusted pillar of your community, suddenly vanishes, leaving you with fewer options for your healthcare needs. This is the reality that Pennsylvania is currently facing, and it's a situation that has left many questioning the effectiveness of a law that was supposed to provide a helping hand.
The Pharmacy Crisis: A Tale of Broken Promises
In Harrisburg, a bipartisan group of lawmakers is raising concerns about the Shapiro administration's handling of a 2024 law aimed at supporting pharmacies. Despite the law's good intentions, hundreds of pharmacies have closed their doors over the past year, leaving patients and pharmacists alike grappling with the consequences.
The law, known as Act 77, was meant to hold corporate middlemen, or pharmacy benefit managers (PBMs), accountable for their practices. These PBMs manage drug plans for employers and insurance companies, but critics argue that they drive up drug costs and offer inadequate reimbursements to community pharmacies.
State Senator Lindsey Williams, one of the lawmakers who signed a letter questioning the enforcement of Act 77, wants pharmacists to feel that PBMs are truly being held to account. She believes the legislation is a step in the right direction, but acknowledges that more needs to be done to ensure its intent is fulfilled.
When Governor Josh Shapiro signed Act 77, he blamed PBMs' greed and conduct for independent pharmacy closures. The law aimed to limit their unfair profit-making practices and force them to disclose key information about rebates and administrative fees. However, the law's limitations have become apparent, as closures continue to occur.
The Limits of Act 77
Act 77's protections and requirements only apply to a fraction of the state's health insurance market - around 24%, according to the Shapiro administration. This exclusion has raised concerns among pharmacy advocates, who worry that the law's impact is not as far-reaching as it should be.
Despite these limitations, Pennsylvania Insurance Commissioner Michael Humphreys has expressed optimism about the law's potential to bring transparency and fairness to the healthcare system. However, a letter signed by six state senators, including four Democrats and two Republicans, highlights the ongoing struggles faced by pharmacies. The letter states that pharmacies are still dealing with unsustainable reimbursement rates and predatory practices, particularly in underserved and rural areas.
The Shapiro administration has defended its approach, acknowledging some confusion over the law's rollout timeline. However, critics argue that effective policy requires effective implementation and enforcement, and they are concerned that this is lacking.
The Impact of Closures
The closures have had a real impact on patients and pharmacists. Patients may have to travel further, wait longer, and even face disruptions in their medication supply. According to state records, about 1,100 licensed Pennsylvania pharmacies went out of business from early 2020 to early November of this year, resulting in a net loss of hundreds of pharmacies.
Rite Aid, a major player in the industry, has been particularly affected, with about 500 of its stores closing. While Rite Aid's financial troubles played a role, its collapse has shed light on the broader issues facing the pharmacy industry.
The Debate Over PBMs
A spokesperson for an association representing PBMs argues that it's unfair to blame them for pharmacy closures. They claim that these companies work to reduce drug costs and save money for patients and the healthcare system as a whole.
However, Greg Lopes, a spokesperson for the Pharmaceutical Care Management Association, acknowledges that there are multiple factors influencing closures, including high drug prices, customer preferences for online options, and population declines in rural areas.
New Oversight Powers and Transparency
Act 77 was designed to address a range of issues by imposing new requirements on prescriptions filled through certain insurance plans. It aimed to create a more level playing field between pharmacies and PBMs.
The law addresses patient steering, clawbacks, and spread pricing, all practices that critics say harm consumers and pharmacies. It also empowers the Insurance Department to review the impact of these practices on prescription drug costs and pharmacy access.
Additionally, Act 77 introduces new transparency requirements for PBMs, including annual reports detailing administrative fees, rebates, and reimbursement differences between affiliated and non-affiliated pharmacies. The Shapiro administration believes that increased transparency will prevent PBMs from engaging in predatory practices that drive up profits.
Concerns Over Enforcement
Despite these new powers and restrictions, some lawmakers remain concerned about the law's implementation. In a letter to the Insurance Department, six state senators raised detailed questions about the agency's actions, including guidance for specialty drugs, appeals received, and the status of studies into patient steering and spread pricing.
The senators also sent separate questions to the Pennsylvania Department of Human Services regarding prescriptions filled through the state's Medicaid program, which is not covered by Act 77. They expressed concern over the low reimbursements through Medicaid, which are intended for low-income individuals.
In response, Human Services Secretary Valerie Arkoosh outlined changes and enforcement actions taken in recent years, as well as a reduction in pharmacy complaints.
Lawmakers have followed up with legislative hearings and additional letters to the Shapiro administration, expressing their ongoing concerns and seeking further action.
Looking Ahead
Aspects of Act 77 are expected to be implemented in 2026, with insurance plans covered by the law beginning to include its protections. The first annual transparency reports are due in July, and the Insurance Department hopes to have results from a study into benefit manager business practices by the new year.
The Shapiro administration maintains that the law's transparency provisions will benefit everyone by providing a better understanding of how PBMs operate.
State Representative Jessica Benham, the prime sponsor of the bill that became Act 77, describes it as a good first step but acknowledges that more needs to be done. She supports further legislative action at both the federal and state levels and believes that additional funding for the Insurance Department could help resolve implementation issues.
The pharmacy crisis in Pennsylvania is a complex issue, and while Act 77 represents a step forward, it is clear that there is still much work to be done to ensure the sustainability and accessibility of community pharmacies.
What are your thoughts on this matter? Do you think Act 77 goes far enough, or is there more that can be done to support pharmacies and patients? We'd love to hear your opinions in the comments below!
